Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.
Dr. Reddy's CEO GV Prasad says the generic drugmaker’s top priority is to do what is needed to get its manufacturing up to FDA expectations.
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Problems at Lupin’s plant in Goa, India, hit the drugmaker’s latest earnings with a double whammy, undercutting its U.S. sales while raising costs.
India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.…
India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…